Naturally Splendid Enterprises Ltd. (NSPDF)
USD 0.04
(0.0%)
USD 0.04
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2022 | - CAD | -100.0% |
| 2021 | 4.27 Million CAD | 5.45% |
| 2020 | 4.05 Million CAD | -27.63% |
| 2019 | 5.6 Million CAD | -14.75% |
| 2018 | 6.56 Million CAD | -1.74% |
| 2017 | 6.68 Million CAD | 9.88% |
| 2016 | 6.08 Million CAD | 34.95% |
| 2015 | 4.5 Million CAD | 502.51% |
| 2014 | 748.36 Thousand CAD | -9.9% |
| 2013 | 830.56 Thousand CAD | 631.5% |
| 2012 | 113.54 Thousand CAD | -31.56% |
| 2011 | 165.9 Thousand CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q2 | - CAD | 0.0% |
| 2023 Q1 | - CAD | 0.0% |
| 2023 Q3 | - CAD | 0.0% |
| 2022 Q1 | 3.82 Million CAD | -10.49% |
| 2022 Q3 | 2.32 Million CAD | -14.65% |
| 2022 FY | - CAD | -100.0% |
| 2022 Q2 | 2.72 Million CAD | -28.67% |
| 2022 Q4 | - CAD | -100.0% |
| 2021 Q3 | 3.15 Million CAD | -1.83% |
| 2021 Q4 | 4.27 Million CAD | 35.39% |
| 2021 Q1 | 4.12 Million CAD | 1.71% |
| 2021 FY | 4.27 Million CAD | 5.45% |
| 2021 Q2 | 3.21 Million CAD | -21.99% |
| 2020 Q2 | 4.5 Million CAD | -5.06% |
| 2020 FY | 4.05 Million CAD | -27.63% |
| 2020 Q4 | 4.05 Million CAD | -11.09% |
| 2020 Q1 | 4.74 Million CAD | -15.3% |
| 2020 Q3 | 4.55 Million CAD | 1.22% |
| 2019 Q1 | 7.48 Million CAD | 13.89% |
| 2019 FY | 5.6 Million CAD | -14.75% |
| 2019 Q4 | 5.6 Million CAD | -33.32% |
| 2019 Q2 | 7.66 Million CAD | 2.46% |
| 2019 Q3 | 8.39 Million CAD | 9.56% |
| 2018 Q3 | 7.19 Million CAD | -3.04% |
| 2018 Q2 | 7.42 Million CAD | -10.45% |
| 2018 Q1 | 8.29 Million CAD | 24.01% |
| 2018 FY | 6.56 Million CAD | -1.74% |
| 2018 Q4 | 6.56 Million CAD | -8.74% |
| 2017 Q1 | 6.22 Million CAD | 2.38% |
| 2017 FY | 6.68 Million CAD | 9.88% |
| 2017 Q2 | 5.84 Million CAD | -6.18% |
| 2017 Q3 | 5.36 Million CAD | -8.28% |
| 2017 Q4 | 6.68 Million CAD | 24.73% |
| 2016 Q1 | 5.22 Million CAD | 15.9% |
| 2016 Q2 | 5.6 Million CAD | 7.33% |
| 2016 FY | 6.08 Million CAD | 34.95% |
| 2016 Q4 | 6.08 Million CAD | -15.63% |
| 2016 Q3 | 7.21 Million CAD | 28.59% |
| 2015 Q4 | 4.5 Million CAD | -37.8% |
| 2015 Q2 | 7.71 Million CAD | 112.98% |
| 2015 Q1 | 3.62 Million CAD | 384.19% |
| 2015 FY | 4.5 Million CAD | 502.51% |
| 2015 Q3 | 7.24 Million CAD | -6.07% |
| 2014 Q4 | 748.36 Thousand CAD | -22.99% |
| 2014 Q2 | 1.5 Million CAD | 127.41% |
| 2014 Q1 | 659.95 Thousand CAD | -20.54% |
| 2014 FY | 748.36 Thousand CAD | -9.9% |
| 2014 Q3 | 971.79 Thousand CAD | -35.25% |
| 2013 Q4 | 830.56 Thousand CAD | 11.56% |
| 2013 Q2 | 966.01 Thousand CAD | -22.68% |
| 2013 Q1 | 1.24 Million CAD | 1000.3% |
| 2013 FY | 830.56 Thousand CAD | 631.5% |
| 2013 Q3 | 744.49 Thousand CAD | -22.93% |
| 2012 Q1 | 152.37 Thousand CAD | -8.15% |
| 2012 Q3 | 95.47 Thousand CAD | -6.92% |
| 2012 Q4 | 113.54 Thousand CAD | 18.92% |
| 2012 FY | 113.54 Thousand CAD | -31.56% |
| 2012 Q2 | 102.57 Thousand CAD | -32.69% |
| 2011 Q4 | 165.9 Thousand CAD | -13.48% |
| 2011 Q3 | 191.75 Thousand CAD | 302.27% |
| 2011 Q2 | 47.66 Thousand CAD | -30.73% |
| 2011 Q1 | 68.82 Thousand CAD | 0.0% |
| 2011 FY | 165.9 Thousand CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | 100.0% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 100.0% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 100.0% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | 100.0% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 100.0% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 100.0% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | 100.0% |
| Mesoblast Limited | 667.9 Million USD | 100.0% |
| Marizyme, Inc. | 22.01 Million USD | 100.0% |
| Genus plc | 1.02 Billion USD | 100.0% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 100.0% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | 100.0% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 100.0% |
| ContraFect Corporation | 20.67 Million USD | 100.0% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | 100.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | NaN% |
| IMV Inc. | 31.33 Million USD | 100.0% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 100.0% |
| MultiCell Technologies, Inc. | 126.22 USD | 100.0% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 100.0% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 100.0% |
| EV Biologics, Inc. | 431.71 Thousand USD | 100.0% |
| Q BioMed Inc. | 3.51 Million USD | 100.0% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 100.0% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | 100.0% |
| Biomind Labs Inc. | 73.81 Thousand USD | 100.0% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 100.0% |
| Skye Bioscience, Inc. | 11.94 Million USD | 100.0% |
| SQZ Biotechnologies Company | 107.18 Million USD | 100.0% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 100.0% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 100.0% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 100.0% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 100.0% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 100.0% |
| TetraLogic Pharmaceuticals Corporation | - USD | NaN% |
| Pharming Group N.V. | 462.85 Million USD | 100.0% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 100.0% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 100.0% |
| GB Sciences, Inc. | 103.44 Thousand USD | 100.0% |
| Alpha Cognition Inc. | 2.45 Million USD | 100.0% |
| argenx SE | 4.54 Billion USD | 100.0% |
| HST Global, Inc. | 1526.00 USD | 100.0% |
| Halberd Corporation | 10.13 Thousand USD | 100.0% |
| Enzolytics Inc. | 361.7 Million USD | 100.0% |
| Resverlogix Corp. | 8.11 Million USD | 100.0% |
| Arno Therapeutics, Inc. | - USD | NaN% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 100.0% |
| MetaStat, Inc. | - USD | NaN% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 100.0% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 100.0% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 100.0% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 100.0% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 100.0% |
| GlobeStar Therapeutics Corporation | - USD | NaN% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | 100.0% |
| GeneThera, Inc. | - USD | NaN% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 100.0% |
| AVAX Technologies, Inc. | 7.37 Million USD | 100.0% |
| ONE Bio Corp. | 70.08 Million USD | 100.0% |
| Zenith Capital Corp. | 7410.00 USD | 100.0% |
| Genscript Biotech Corporation | 3.38 Billion USD | 100.0% |
| Ember Therapeutics, Inc. | 184.00 USD | 100.0% |
| Anthera Pharmaceuticals, Inc. | - USD | NaN% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | 100.0% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | 100.0% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 100.0% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 100.0% |
| Agentix Corp. | 261.39 Thousand USD | 100.0% |
| Adynxx, Inc. | - USD | NaN% |
| Kadimastem Ltd | 2.3 Million USD | 100.0% |
| Helix BioMedix, Inc. | 3.02 Million USD | 100.0% |
| VitaSpring Biomedical Co. Ltd. | - USD | NaN% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 100.0% |
| BioStem Technologies, Inc. | 14.56 Million USD | 100.0% |
| Oncology Pharma Inc. | - USD | NaN% |
| Reve Technologies, Inc. | 57.09 Thousand USD | 100.0% |
| Burzynski Research Institute, Inc. | 2310.00 USD | 100.0% |
| LadRx Corporation | 2.3 Million USD | 100.0% |
| Cell Source, Inc. | 195.17 Thousand USD | 100.0% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | 100.0% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 100.0% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 100.0% |
| NovAccess Global Inc. | 62.24 Thousand USD | 100.0% |
| Affymax, Inc. | 7.44 Million USD | 100.0% |
| Itoco Inc. | 1.4 Million USD | 100.0% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | 100.0% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | 100.0% |
| CytoDyn Inc. | 11.13 Million USD | 100.0% |
| Claritas Pharmaceuticals, Inc. | - USD | NaN% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | 100.0% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | 100.0% |
| Qrons Inc. | 420.00 USD | 100.0% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | 100.0% |
| SYBLEU INC | 330.46 Thousand USD | 100.0% |
| Advanced Proteome Therapeutics Corporation | - USD | NaN% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 100.0% |
| Rebus Holdings, Inc. | 5000.00 USD | 100.0% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | 100.0% |
| Mobile Lads Corp. | 52.00 USD | 100.0% |
| International Stem Cell Corporation | 5.39 Million USD | 100.0% |
| Bioxytran, Inc. | 137.63 Thousand USD | 100.0% |
| GlobeImmune, Inc. | - USD | NaN% |
| Predictive Technology Group, Inc. | - USD | NaN% |
| ProText Mobility, Inc. | 15 Million USD | 100.0% |
| Cardax, Inc. | - USD | NaN% |
| VG Life Sciences Inc. | - USD | NaN% |
| Kaleido Biosciences, Inc. | - USD | NaN% |
| Advaxis, Inc. | 16.57 Million USD | 100.0% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | 100.0% |
| RenovaCare, Inc. | - USD | NaN% |
| Regnum Corp. | 864.67 Thousand USD | 100.0% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 100.0% |
| Neutra Corp. | 2851.00 USD | 100.0% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 100.0% |
| PureTech Health plc | 693.97 Million USD | 100.0% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 100.0% |
| IXICO plc | 15.84 Million USD | 100.0% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 100.0% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 100.0% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Cellectis S.A. | 333.99 Million USD | 100.0% |